Search

Your search keyword '"Callejo, Ana"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Callejo, Ana" Remove constraint Author: "Callejo, Ana"
172 results on '"Callejo, Ana"'

Search Results

1. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer

7. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

8. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

9. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

10. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer

15. 178: Multimodality treatment in synchronous oligometastatic NSCLC: final analysis of the ETOP CHESS trial

17. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients

18. Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC

19. T-cell infiltration in matched samples from malignant pleural mesothelioma (MPM) during evolution of disease.

20. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer

21. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

24. Longitudinal Evolution of Cognitive Function in Colorectal and Breast Cancer Survivors Treated with (Neo)Adjuvant Chemotherapy.

25. Efficacy of Chemotherapy for Malignant Pleural Mesothelioma According to Histology

29. Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients

30. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

31. Analysis of chemotherapy efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p).

32. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

33. Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer

36. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

37. Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1).

38. Genomic alterations profiling by liquid biopsy and their association to immune checkpoints inhibitors (ICI) response in a cohort of non-small cell lung cancer (NSCLC) patients.

39. SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.

40. Asthma Caused by a Cathedral Wall

41. Anaphylaxis associated with antiphospholipid syndrome

42. Abstract B050: Validation of body mass index (BMI) as a prognostic factor in patients (pts) treated with immune checkpoint inhibitors (ICI) across multiple cancer types (CT) and the impact of confounding factors (CF)

43. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.

44. Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs).

46. Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).

Catalog

Books, media, physical & digital resources